Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute

Takaya Yamamoto, Yoshihide Kawasaki, Rei Umezawa, Noriyuki Kadoya, Haruo Matsushita, Kazuya Takeda, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Ken Takeda, Kousei Kawabata, Akihiro Ito, Keiichi Jingu

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


The purpose of this retrospective study was to investigate survival outcomes and irradiated tumor control (local control [LC]) and locoregional control (LRC) after stereotactic body radiotherapy (SBRT) for T1 or recurrent T1 (rT1) kidney cancer. Twenty-nine nonconsecutive patients with 30 tumors were included. SBRT doses of 70 Gy, 60 Gy or 50 Gy in 10 fractions were prescribed with a linear accelerator using daily image guidance. The Kaplan-Meier method was used to estimate time-to-event outcomes, and the log-rank test was used to compare survival curves between groups divided by each possible factor. The median follow-up periods for all patients and survivors were 57 months and 69.6 months, respectively. The five-year LC rate, LRC rate, progression-free survival (PFS) rate, disease-specific survival (DSS) rate and overall survival (OS) rate were 94%, 88%, 50%, 96% and 68%, respectively. No significant factor was related to OS and PFS. Three of 24 non-hemodialysis (HD) patients had new-onset-HD because of the progression of underlying kidney disease. Grade 3 or higher toxicities from SBRT did not occur. In conclusion, SBRT for kidney cancer provided a high rate of LC, LRC and DSS with minimal toxicities, but patient selection and indication for SBRT should be done carefully considering the relatively low OS rate.

Original languageEnglish
Pages (from-to)533-539
Number of pages7
JournalJournal of Radiation Research
Issue number3
Publication statusPublished - 2021 May 1


  • kidney cancer
  • local control (LC)
  • renal cell carcinoma
  • stereotactic body radiotherapy (SBRT)


Dive into the research topics of 'Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute'. Together they form a unique fingerprint.

Cite this